array(35) { ["id"]=> string(4) "2092" ["type"]=> string(6) "course" ["title"]=> string(61) "有理想真的有前途吗 ——创新药企的未来探索" ["subtitle"]=> string(0) "" ["creator"]=> array(6) { ["id"]=> string(1) "3" ["nickname"]=> string(5) "admin" ["title"]=> string(1) " " ["uuid"]=> string(40) "634d3b58166bfafd4069119be97ee6bfee064c52" ["destroyed"]=> string(1) "0" ["avatar"]=> array(3) { ["small"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" ["middle"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" ["large"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" } } ["showable"]=> string(1) "1" ["buyable"]=> string(1) "1" ["summary"]=> string(918) "

在当今医疗健康产业中，恒瑞医药与药明康德作为行业先锋，以自主研发和外包服务两种不同的发展模式探索前进。恒瑞医药怀揣着自主创新的理想，持续加大研发投入，铸就了坚实的专利壁垒，但也面临研发周期长、风险高的挑战。而药明康德则通过其独特的Contract Development and Manufacturing Organization（CDMO）模式，提供从药物发现到商业化生产的一体化服务，降低研发成本并缩短新药上市周期，然而，作为外包服务提供商，其业务表现易受外部市场和政策环境的影响。因此，对这两家典型企业的深入分析显得尤为重要，我们将从财务表现、研发投入与创新能力、资产价值等多个维度进行探讨，并对药企行业的大数据进行分析，以期为我国创新药企行业的发展提供有益的参考和借鉴。

" ["minPrice"]=> string(4) "0.00" ["maxPrice"]=> string(4) "0.00" ["discountId"]=> string(1) "0" ["images"]=> array(3) { ["large"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e0089e192590.jpeg" ["middle"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e01f2f181086.jpeg" ["small"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e02618779023.jpeg" } ["ratingNum"]=> string(1) "0" ["rating"]=> string(1) "0" ["hitNum"]=> string(3) "111" ["hotSeq"]=> string(1) "0" ["maxPriceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["minPriceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["minDisplayPrice"]=> string(4) "0.00" ["maxDisplayPrice"]=> string(4) "0.00" ["minDisplayPriceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["maxDisplayPriceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["canManage"]=> bool(false) ["peopleShowNum"]=> string(3) "112" ["isMember"]=> bool(false) ["status"]=> string(7) "created" ["orgId"]=> string(1) "1" ["orgCode"]=> string(2) "1." ["recommendWeight"]=> string(1) "0" ["recommendedTime"]=> string(1) "0" ["createdTime"]=> string(25) "2025-01-13T17:11:12+08:00" ["updatedTime"]=> string(25) "2025-12-10T13:16:29+08:00" ["product"]=> array(7) { ["id"]=> string(4) "2093" ["targetType"]=> string(6) "course" ["title"]=> string(61) "有理想真的有前途吗 ——创新药企的未来探索" ["owner"]=> string(1) "3" ["createdTime"]=> string(10) "1736759472" ["updatedTime"]=> string(10) "1742448265" ["target"]=> array(17) { ["id"]=> string(4) "2214" ["type"]=> string(6) "normal" ["title"]=> string(61) "有理想真的有前途吗 ——创新药企的未来探索" ["subtitle"]=> string(0) "" ["summary"]=> string(918) "

在当今医疗健康产业中，恒瑞医药与药明康德作为行业先锋，以自主研发和外包服务两种不同的发展模式探索前进。恒瑞医药怀揣着自主创新的理想，持续加大研发投入，铸就了坚实的专利壁垒，但也面临研发周期长、风险高的挑战。而药明康德则通过其独特的Contract Development and Manufacturing Organization（CDMO）模式，提供从药物发现到商业化生产的一体化服务，降低研发成本并缩短新药上市周期，然而，作为外包服务提供商，其业务表现易受外部市场和政策环境的影响。因此，对这两家典型企业的深入分析显得尤为重要，我们将从财务表现、研发投入与创新能力、资产价值等多个维度进行探讨，并对药企行业的大数据进行分析，以期为我国创新药企行业的发展提供有益的参考和借鉴。

" ["cover"]=> array(3) { ["large"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e0089e192590.jpeg" ["middle"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e01f2f181086.jpeg" ["small"]=> string(76) "http://www.chinadatacase.com/files/course/2025/03-20/132358e02618779023.jpeg" } ["status"]=> string(9) "published" ["studentNum"]=> string(3) "112" ["discountType"]=> string(8) "discount" ["discount"]=> string(2) "10" ["minCoursePrice"]=> string(4) "0.00" ["maxCoursePrice"]=> string(4) "0.00" ["defaultCourseId"]=> string(4) "2220" ["productId"]=> string(4) "2093" ["goodsId"]=> string(4) "2092" ["minCoursePrice2"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["maxCoursePrice2"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } } } ["extensions"]=> array(3) { [0]=> string(8) "teachers" [1]=> string(14) "recommendGoods" [2]=> string(10) "isFavorite" } ["specs"]=> array(1) { [0]=> array(26) { ["id"]=> string(4) "2119" ["goodsId"]=> string(4) "2092" ["targetId"]=> string(4) "2220" ["title"]=> string(0) "" ["seq"]=> string(1) "1" ["status"]=> string(9) "published" ["price"]=> string(4) "0.00" ["coinPrice"]=> string(4) "0.00" ["usageMode"]=> string(7) "forever" ["usageDays"]=> string(1) "0" ["usageStartTime"]=> string(1) "0" ["usageEndTime"]=> string(1) "0" ["buyableStartTime"]=> string(1) "0" ["buyableEndTime"]=> string(1) "0" ["buyableMode"]=> NULL ["buyable"]=> string(1) "1" ["maxJoinNum"]=> string(1) "0" ["services"]=> array(0) { } ["priceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["displayPrice"]=> string(4) "0.00" ["displayPriceObj"]=> array(2) { ["currency"]=> string(3) "RMB" ["amount"]=> string(4) "0.00" } ["isMember"]=> bool(false) ["access"]=> array(2) { ["code"]=> string(14) "user.not_login" ["msg"]=> string(15) "用户未登录" } ["hasCertificate"]=> bool(false) ["learnUrl"]=> string(43) "http://www.chinadatacase.com/my/course/2220" ["teachers"]=> array(1) { [0]=> array(6) { ["id"]=> string(1) "3" ["nickname"]=> string(5) "admin" ["title"]=> string(1) " " ["uuid"]=> string(40) "634d3b58166bfafd4069119be97ee6bfee064c52" ["destroyed"]=> string(1) "0" ["avatar"]=> array(3) { ["small"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" ["middle"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" ["large"]=> string(75) "http://www.chinadatacase.com/files/user/otherform/1711697442_1722994936.png" } } } } } } 有理想真的有前途吗 ——创新药企的未来探索 - 中国经管实验教学案例平台

中国经管实验教学案例平台

www.chinadatacase.com